© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Mefenamic acid stands as a recognized nonsteroidal anti-inflammatory drug (NSAID), widely used for its potent abilities to ease mild to moderate pain and to bring down inflammation. As a prescription medication, it has gained worldwide acceptance in the treatment of conditions such as menstrual cramps, headaches, toothaches, and certain muscle discomforts. The chemical draws a lot of interest not only in the clinical field, but also across the chemical manufacturing sector due to its distinct profile, physical form, and safety concerns.
Mefenamic acid carries the molecular formula C15H15NO2. Its molecular weight stands around 241.29 g/mol. The molecule features a fenamate structure—anchored by an anthranilic acid backbone modified by a 2,3-dimethylphenyl group. These features drive both its anti-inflammatory property and the way it behaves when handled as a raw material. On a molecular level, strong hydrogen bonding tends to happen around its carboxylic acid group, which directly shapes the solubility, stability, and how easy or hard it is to convert it from solid to liquid for formulations.
Whether you look at a pharmaceutical plant or a chemical wholesaler, mefenamic acid almost always presents as a white to off-white crystalline solid. No strong odor, no striking color—just a clean appearance. Flake, powder, pearl, and sometimes granular forms pop up in different raw material supply chains, reflecting the needs of precise material handling and desired solubility for finished products. Density settles close to 1.27 g/cm³, a value that comes into play during storage, shipping, and blending in bulk batches. As a raw material, it does not show the easy flowability of tiny pearls or microcrystalline powders, so extra care often goes into ensuring it gets measured and dissolved correctly.
Mefenamic acid is almost water-insoluble, but dissolves fairly well in organic solvents like chloroform, acetone, ethanol, and ether. This low water solubility gives it a certain edge and a challenge—it prevents easy leaching in aqueous mixtures, but forces formulators to use solvents or special processing if they want to create a solution or suspension. Solid at normal temperatures, it melts around 230-231°C. During production and quality assurance, the material rarely appears as a true liquid or clear solution unless subjected to significant heating or dissolved in suitable solvent systems.
For customs and international trade, mefenamic acid falls under HS Code 2916.39, which groups together aromatic monocarboxylic acids and derivatives. Warehouses stock it in well-sealed, light-resistant containers, protected from moisture and extreme temperatures. As someone who has visited several API (Active Pharmaceutical Ingredient) warehouses, one thing becomes clear pretty fast—material integrity hangs on strict storage conditions. Let it absorb a little moisture, and clumping or slow degradation takes hold, with real consequences for downstream pharmaceutical manufacturing.
Handling mefenamic acid in a chemical plant or pharmacy setting brings legitimate health concerns. Dust inhalation causes respiratory discomfort. Skin or eye contact can lead to irritation. In pharmaceutical settings, operators rely on gloves, dust masks or respirators, and buckets of water for accidental splashes. On a chemical safety data sheet, warnings about ingestion, prolonged contact, and environmental spill control stand out. Regulatory authorities—FDA, EMA, national ministries—demand clear labeling and careful record-keeping for this compound. In raw form, mefenamic acid does not explode or burn easily, but in fine powders, attention to dust control and prevention of accidental release cannot be ignored.
Disposing of mefenamic acid waste demands full compliance with regional and global environmental protection rules. From my time consulting in cleanroom environments, improper disposal earns quick regulatory penalties and can lead to contamination of local waterways and soil. Waste management protocols include collection of solid residues, safe storage in appropriate containers, and coordination with licensed hazardous waste handlers. Auditors look for every detail—labeling, access control, records of how much raw material came in, was used, and was sent out as waste.
Input from chemical engineers and production staff reveals clear priorities. Eliminating dust during weighing and transfer makes the process safer and cleaner. Automated dispensing, enclosed transfer systems, and real-time monitoring of environmental conditions decrease the risks linked to this chemical raw material. Batch testing for purity—especially when buying from new or international suppliers—protects against counterfeit or degraded material entering the production chain. Equipment cleaning between runs prevents cross-contamination. When blending or dissolving mefenamic acid, using approved solvents and temperature controls leads to a more stable and consistent product, reducing wastage and off-specification batches.
Real experience in pilot plants points to one practical lesson: never neglect staff training on chemical hazards, and invest in quality protective gear. Clear signage and well-lit storage areas narrow the chance of accidents or accidental mix-ups with other, visually similar powders. Batch tracking, by barcode or digital ledger, ensures that if a recall ever needs to happen, the process can move fast and precise. Collaborations with reliable suppliers cut down risks of contamination, substitution, or delivery delays that can put pharmaceutical production schedules in disarray. At the end of the day, solid safety culture and operational discipline make sure this material brings relief to those who need it, and doesn’t endanger workers or the environment.
